Quidel's Q2 Revenues Fall 4 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Quidel reported after the close of the market Tuesday that its second-quarter revenues declined 4 percent year over year, due primarily to lower sales of its infectious disease diagnostic products.

The San Diego, Calif.-based diagnostics firm brought in total revenues of $29.7 million for the three months ended June 30, compared to $30.9 million for the second quarter of 2012. Analysts, on average had expected revenues of $33.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.